Former KL2 scholar, Christopher Seet, receives grant to support the development of cell-based cancer therapies
The prestigious grant is a $2.9 million R37 MERIT Award from the National Cancer Institute
Christopher Seet, MD, PhD, assistant professor of hematology-oncology at the David Geffen School of Medicine, has been awarded a R37 MERIT Award, a research grant for $2.9 million from the National Cancer Institute. Seet, who is also a former UCLA CTSI KL2 Scholar, will use the funds to support the development of T cell therapies, a form of immunotherapy involving stem cell engineering to destroy cancer cells.
R37 MERIT grants are given to early-career scientists who have submitted the highest-scoring R01 grant proposals, offering an additional two years of research funding beyond the typical five-year R01 grant duration.
Dr. Seet was a UCLA Clinical and Translational Sciences Institute (CTSI) KL2 Scholar from 2017-2019. During his time in the program, his KL2 mentors included Dr. Gay Crooks and Dr. Owen Witte of UCLA.
For more information about the KL2 Translational Science Scholars program, visit the KL2 homepage.
Photo source: UCLA